Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Aubagio Teriflunomide Multiple sclerosis, relapsing-remitting Do not list at the submitted price Complete
Avastin Bevacizumab Cervical Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Platinum Resistant Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Withdrawn
Avastin (with capecitabine) Bevacizumab Metastatic Colorectal Cancer Reimburse with clinical criteria and/or conditions Complete
Avodart Dutasteride Prostatic hyperplasia, benign List in a similar manner to other drugs in class Complete
Axert Almotriptan Migraine List in a similar manner to other drugs in class Complete
Azarga Brinzolamide and timolol maleate suspension Glaucoma and ocular hypertension List in a similar manner to other drugs in class Complete
Azilect Rasagiline mesylate Parkinson's disease Do not list Complete